Motif Bio (LON:MTFB)‘s stock had its “buy” rating reaffirmed by stock analysts at Northland Securities in a research report issued on Wednesday.

Several other equities analysts also recently commented on the company. Peel Hunt reiterated a “buy” rating on shares of Motif Bio in a research note on Wednesday. Northland Capital Partners reiterated a “buy” rating on shares of Motif Bio in a research note on Monday, June 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of GBX 109.40 ($1.42).

Motif Bio stock opened at GBX 31.61 ($0.41) on Wednesday. Motif Bio has a 12 month low of GBX 23.50 ($0.30) and a 12 month high of GBX 51.75 ($0.67).

Motif Bio Company Profile

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

See Also: Book Value Per Share – BVPS

Analyst Recommendations for Motif Bio (LON:MTFB)

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.